The proxy fight outcome is binary and will be resolved at the June 9 meeting. With all three major proxy advisors backing management, the incumbent slate is heavily favored. A DOMA win would introduce significant uncertainty around capital allocation and strategic direction. Monitor vote results post-meeting for potential board composition changes.
Price Chart
Executive Summary
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominees (Christopher Christie, Samit Hirawat, MD, Thomas Wiggans) on the BLUE proxy card at the June 9, 2026 annual meeting, and AGAINST all three nominees from activist investor DOMA Perpetual Capital Management. The filing highlights record 2025 financial results, Q1 2026 revenue growth across all commercial products (EXPAREL +5%, ZILRETTA +15%, iovera +21% YoY), and endorsements from all three leading proxy advisory firms (ISS, Glass Lewis, Egan-Jones) supporting management's slate.
Key Facts
- Annual meeting scheduled for June 9, 2026
- Management nominees: Christopher Christie, Samit Hirawat, MD, Thomas Wiggans
- Activist DOMA Perpetual Capital Management nominated three director candidates
- All three proxy advisory firms (ISS, Glass Lewis, Egan-Jones) recommend FOR management's nominees
- Q1 2026 EXPAREL revenue $143.3M (+5% YoY), ZILRETTA $26.8M (+15%), iovera $6.2M (+21%)
- 2025 record total revenue $726.4M, GAAP gross margin 79.4%, non-GAAP gross margin 81.2%
- Goldman Sachs acting as financial advisor, Perkins Coie as legal counsel
- Key pipeline catalysts expected in 2026: Phase 2 PCRX-201 data in knee OA, registrational studies for ZILRETTA (shoulder OA) and iovera (spasticity)
Financial Impact
Record 2025 revenue of $726.4M with 79.4% GAAP gross margin; Q1 2026 product revenue growth of 5-21% YoY across portfolio
Risk Factors
- Activist DOMA could win board seats despite proxy advisor opposition, potentially disrupting strategy
- Pipeline readouts (PCRX-201 Phase 2, registrational studies) carry binary clinical risk
- Revenue growth is modest (5-21% across products) and may not satisfy activist demands for faster value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-040814 |
| Document: 0001628280-26-040814-index-headers.html | 0001628280-26-040814 |
| Document: 0001628280-26-040814-index.html | 0001628280-26-040814 |
| Document: 0001628280-26-040814.txt | 0001628280-26-040814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access